• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Pregnancy Prolongation in Women with Early-Onset Preeclampsia: What is the Impact on Postpartum Fetal and Maternal Outcomes?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Mulder et al. (BJOG, 2020) examined the associations between deferred delivery in early-onset preeclampsia, fetal consequences, and maternal cardiovascular outcomes

METHODS:

  • Observational study (1996 to 2018)
  • Participants
    • Nulliparous women diagnosed with preeclampsia <34 weeks within 2 years of delivery | <24 weeks excluded
    • Women were participants in a routine postpartum cardiovascular risk assessment program
    • Excluded: Women with hypertension, diabetes mellitus or renal disease prior to pregnancy
  • Study design
    • The association between pregnancy prolongation and outcome measures were analyzed using regression analysis to account for confounding
  • Primary outcomes
    • Offspring outcomes
    • Prevalence of decreased maternal cardiovascular, renal, and metabolic function

RESULTS:

  • 564 women
    • Median (IQR) pregnancy prolongation: 10 (6 to 12) days
    • HELLP syndrome: 72%
  • Gestational age
    • GA at diagnosis was 30 weeks | GA at delivery was 32 weeks
    • GA at diagnosis was lower in the group of women with the longest pregnancy prolongation (p<0.001 for trend)
  • Pregnancy prolongation after diagnosis resulted in
    • A decrease in infant mortality | Adjusted odd ratio (aOR) 0.907 (95% CI, 0.852 to 0.965) per day prolongation
    • An increase in absolute birthweight when comparing ≤6 days (1278 g) vs ≥14 days (1620 g); p<0.001 for trend
  • Pregnancy prolongation was associated with an elevated risk of moderately increased maternal albuminuria (adjusted for gestational age at delivery, maternal age, year of postpartum assessment, and metabolic syndrome constituents)
    • aOR 1.025 (95% CI, 1.006 to 1.045) per day prolongation
  • There was no association between pregnancy prolongation and
    • Other renal parameters (e.g., Cr clearance)
    • Cardiac geometry (relative wall thickness, LV mass index)
    • Cardiac systolic or diastolic dysfunction (e.g., ejection fraction)
    • Persistent hypertension
    • Metabolic syndrome

CONCLUSION:

  • For women with early-onset preeclampsia, prolonging pregnancy decreased infant mortality and increased birthweight
  • Pregnancy prolongation did not have a negative effect on short-term adverse maternal outcomes, except for an increased risk for albuminuria
  • Limitations of this study include
    • Effect of specific treatment could not be ascertained
    • Detail regarding maternal condition that resulted in delivery was not available
  • The authors note that after preterm preeclampsia, women show persistent cardiovascular remodeling; however, this study did not demonstrate that prolonging pregnancy has much of an impact and they further suggest that

A possible explanation could be that the known association with unfavourable structural alteration in preeclampsia may have already occurred by the time the diagnosis was made 

Learn More – Primary Sources:

Effect of pregnancy prolongation in early‐onset pre‐eclampsia on postpartum maternal cardiovascular, renal and metabolic function in primiparous women: an observational study

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Could Esomeprazole Prolong Pregnancy for Women with Preterm Preeclampsia?
Does Use of Progestogen Prolong Labor in PPROM Pregnancies?
Meis and PROLONG Trials: The Safety Profile for 17-OHPC used to Prevent Preterm Birth

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site